RESEARCH ARTICLE

EXPRESSION OF CD200 IN CD5 POSITIVE B-CELL LYMPHOPROLIFERATIVE DISORDER (B-CLL AND MCL) AND ITS ROLE IN THE DISCRIMINATION BETWEEN THESE DISORDERS.

Dr. Hind shaker al-mamoori.

Abstract

Chronic B-cell lymphoproliferative disorders (B-CLPD) are a group of clonal diseases characterized by proliferations of mature B lymphocytes in the bone marrow (BM), peripheral blood, and lymphoid tissues. Mature B-cell lymphoproliferative disorders is divided by CD5 expression into two groups:

1. CD5 (positive) diseases including B cell chronic lymphocytic leukemia (B-CLL) and mantle cell lymphoma (MCL).
2. CD5 (negative) diseases and including all the other forms of B-CLPD.

Chronic lymphocytic leukemia (B-CLL) and mantle cell lymphoma (MCL) have many features in common and their differential diagnosis may be arduous, particularly when a leukemic phase of lymphoma is the only presentation. Immunophenotypic panels are often useful, with CD23 being the most valid in B-CLL and in MCL suspected cases should be confirmed by immunohistochemically cyclin D1 detection but sometime indefinite or some time negative repercussion may occur and other immunological markers and advanced cytogenetics or molecular techniques are bona fide but they add extra cost and not widely available. So we study the expression of CD 200 which is a membrane gp of the immunoglobulin superfamily in CD 5 positive mature B-cell lymphoproliferative disorders to help in differentiation.

Aim of the study: -

1. To detect the immunohistochemically expression of CD200 in CD5 +ve Mature B-cell lymphoproliferative disorders.
2. Evaluation of the value of CD200 in diagnosis and differentiating between B cell chronic lymphocytic leukemia (B-CLL) and mantle cell lymphoma (MCL).

Patients, materials and methods: -
This cross sectional study included 49 adult patients and newly diagnosed by morphology and flowcytometric immunophenotyping as B-CLL for score 4-5 and MCL with score <4 conducted from February 2015 to September 2016 from many centers, Baghdad teaching hospitals and private clinic. From each patient, left over samples were used.
Bone marrow trephine biopsy sections were stained with hematoxylin and eosin for histopathological assessment further detection for the expression of cyclin D1 and CD200 were performed by immunohistochemistry technique.

**Results:** - The patients were 36 males and 13 females newly diagnosed as CD5 positive mature B-cell lymphoproliferative disorder, 39 patients were presented with B-chronic lymphocytic leukemia and 10 were mantle cell lymphomadiagnosed by morphological assessment and flowcytometric immunophenotyping as B-CLL with score 4-5 and MCL with score <4, MCL diagnosis proved by immunohistochemically expression of cyclin D1. The result showed that CD200 was expressed in 37 (94.9%) out of 39 chronic lymphocytic leukemia patients while mantle cell lymphoma cases were all negative for CD200 expression. Highly significant association between CD200 expression and B-CLL, p value was <0.001 and negative in 2 cases (5.1%) shown to have an advanced disease.

**Conclusions:** - CD200 is highly expressed in B-CLL and it has a discriminative role in mature CD5 positive B-cell lymphoproliferative disorders (B-CLL and MCL). The only CD 200 negative CLL cases might related to the advanced stage of disease.

---

**Introduction:** -

Chronic mature B-cell lymphoproliferative disorders (B-CLPD) are a group of clonal diseases characterized by proliferation of mature looking B lymphocytes in the bone marrow, peripheral blood, and lymphoid tissues. B-CLPD diagnosis can be made by morphological, and immunophenotyping that help in differentiation between different types of mature B-cell lymph proliferative disorders (B-CLPD) and this supported by cytogenetic parameters, as is described in the World Health Organization classification (WHO). (1)

Immunohistochemically immunophenotypic analysis is particularly helpful in establishing the diagnosis because there is significant overlap in clinical and morphologic features between these diseases entities and as the B-CLL and mantle cell lymphoma have many features in common and they may give equivocal or negative result for the specific markers used for differentiation so a more advanced cytogenetic or molecular tests are required but they add extra cost and might not be available. (2)

Such difficult cases of B-CLPDs can be further sub classified according to the expression of CD5. Patients with CD5 negative B-CLPD usually present as the leukemic phase of lymphoma such as marginal zone lymphoma (MZL), lymphoplasmacytic lymphoma (LPL), follicular cell lymphoma (FCL), or hairy cell leukemia (HCL); While patients with CD5 positive B-CLPD can be either B-CLL or mantle cell lymphoma in which differentiations between them may be so difficult as they do not have the characteristic immunophenotypic score of CLL or mantle cell lymphoma (MCL) (i.e. CD5+B-CLPD). (3), (4), (5).

CD200 is a membrane gp MRC (OX-2). It is a member of the immunoglobulin superfamily which is encoded by a gene at chromosome 3q12; This transmembrane protein is expressed on different cell types, and it is expressed by endothelial cells and neurons and by Blymphocyte and a subset of T lymphocyte; It plays an important role in the regulation of anti-tumor immunity (5), and overexpression of CD200 has been reported in a number of malignancies, including CLL, because of its differential expression in B-CLL and mantle cell lymphoma (MCL), we evaluate this expression differences on these two disorders.

**Materials and Methods:** -

This cross sectional study was conducted on 49 adult patients newly diagnosed mature CD5 positive BCLPD. 39 patients were presented with chronic lymphocytic leukemia diagnosis depend on the WHO classification of mature B-cell Neoplasms with score 4-5 and 10 were mantle cell lymphoma score < 4 (1). The diagnosis of which was
confirmed by the demonstration of cyclin D1 expression by immunohistochemistry, the cases were randomly selected for the age and sex.

The samples for each patient were subjected to the following procedures: -
1. Samples were leftover.
2. Bone marrow biopsy was fixed with formalin solution and stained by hematoxylin and eosin for histopathological examination.
3. Immunohistochemistry technique on bone marrow biopsy used to detect CD200 to assess its differential expression on B-CLL and MCL.

Procedures: -
Processing of B.M biopsy and immunohistochemistry: -
Sections slides were stained with hematoxylin and eosin and sections were fixed on positively charged slides for immunohistochemically tests for CD200 each section was with 4-micron thickness, procedure of immunohistochemistry used in this study was adopted by abcam®
All steps are performed at room temperature.

Staining protocol: -
1. Deparaffinize and rehydrate formalin fixed paraffin-embedded tissue section.
2. Add enough drops of hydrogen peroxide block to cover the section. Incubate for 10 minutes. Wash 2 times in buffer.
3. Apply protein block an incubate for 10 minutes at room temperature to block nonspecific background staining.
   Wash 1 time in buffer.
4. Apply primary antibody and incubate.
5. Wash 3 times in buffer solution.
6. Pour complement and incubate for ten minutes at room temperature. Wash 2 times in buffer solution.
7. Pour HRP conjugate and incubate for 15 minutes at RT
8. Rinse four times in buffer solution. Add 30μl (1drop) DAB chromogen to 1.5 ml of DAB substrate, mix by swirling and apply to the tissue. Incubate for 10 minutes. Rinse 4 times in buffer.
9. Apply counter stain
10. Dehydrate and coverslip.

The slides were examined by light microscope and scanned on low and high powers (10x, 40x).
Assessment of immunohistochemically staining: -
The scoring systems for CD200 were scored positive if 20% or more of the cells within an aggregate showed brown cellular membrane and/or cytoplasmic staining pattern. (6)

Statistics: -
A non-parametric two-way contingency table test (Fisher exact test) was employed, using Prism 7 for Mac OS X software, ver. 7.0a (Graph Pad Software, San Diego, California). The validity of CD200 in discrimination of B-CLL than MCL was calculated using sensitivity, specificity, positive and negative predictive values.

Result: -
Thirty-nine patients with B-CLL and ten with MCL were enrolled in this study, patients were randomly selected for the age and sex as shown in the table 1. The male to female ratio in B-CLL cases were 2.5:1 and in MCL were 4:1.

<table>
<thead>
<tr>
<th>Table 1: -age and sex distribution.</th>
<th>Study groups</th>
<th>P value</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>CLL</td>
<td>MCL</td>
</tr>
<tr>
<td><strong>Age (years)</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mean±SD</td>
<td>60.08±11.15</td>
<td>57.7±4.3</td>
</tr>
<tr>
<td>(Minimum-Maximum)</td>
<td>(39-80)</td>
<td>(50-64)</td>
</tr>
<tr>
<td><strong>Sex</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Male (%)</td>
<td>28 (71.8)</td>
<td>8 (80)</td>
</tr>
<tr>
<td>Female (%)</td>
<td>11 (28.2)</td>
<td>2 (20)</td>
</tr>
</tbody>
</table>

1157
Binet stages were available for B-CLL cases and were as shown in table 2

**Table 2:** Binet staging system for B-CLL

<table>
<thead>
<tr>
<th>Binet stage</th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>A</td>
<td>30</td>
<td>76.9%</td>
<td></td>
</tr>
<tr>
<td>B</td>
<td>7</td>
<td>17.9%</td>
<td></td>
</tr>
<tr>
<td>C</td>
<td>2</td>
<td>5.1%</td>
<td></td>
</tr>
<tr>
<td>Peripheral blood lymphocytes (10⁹ per liter)</td>
<td>22.1</td>
<td>15-35</td>
<td></td>
</tr>
<tr>
<td>Hb (g/100 ml)</td>
<td>13</td>
<td>10.5-13.6</td>
<td></td>
</tr>
<tr>
<td>Platelets (10⁹ per liter)</td>
<td>145</td>
<td>95-190</td>
<td></td>
</tr>
</tbody>
</table>

CD200 was expressed by 94.9% of our CLL cases as shown in figure 1 compared with 0% of MCL cases as shown in figure 2. The cut-off value of CD200 percent expression on malignant clone cells in both groups was 20%, it had 99.37% sensitivity, 100% specificity, 100% positive predictive value, and 83.33% negative predictive value as shown in the table 3.

![Figure 1](image1.png)

**Figure 1:** Cytoplasmic positivity for CD200 in B-CLL.

![Figure 2](image2.png)

**Figure 2:** Cytoplasmic negativity for CD200 in MCL.
Table 3: -The CD 200 expression on the two studied groups.

<table>
<thead>
<tr>
<th>Study groups</th>
<th>P value</th>
<th>Sensitivity (CI)</th>
<th>Specificity (CI)</th>
<th>PPV</th>
<th>NPV</th>
<th>Kappa index</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>CD200 positive (%)</td>
<td>&lt;0.001**</td>
<td>94.87</td>
<td>100</td>
<td>100</td>
<td>83.33</td>
<td>0.883</td>
</tr>
<tr>
<td>(94.9)</td>
<td></td>
<td>82.68 to 99.37</td>
<td>69.15 to 100.00</td>
<td></td>
<td>56.45 to 95.07</td>
<td></td>
</tr>
<tr>
<td>CD200 negative (%)</td>
<td>37 (94.9)</td>
<td>0 (0%)</td>
<td>100</td>
<td>69.15 to 100.00</td>
<td>83.33</td>
<td>0.883</td>
</tr>
<tr>
<td>(5.10)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>56.45 to 95.07</td>
<td></td>
</tr>
<tr>
<td>Total</td>
<td>39</td>
<td>10</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Discussion:
Chronic mature B-cell lymphoproliferative disorders (B-CLPD) are a group of malignant diseases marked by accumulation of mature looking B lymphocytes in the bone marrow, peripheral blood, and lymphoid tissues. B-CLL and MCL both are CD5+ve mature B lymphocyte neoplasms that show differences in the outcomes, modality of treatment and outcomes; B-CLL tends to follow an indolent course, having median survival ranging from 8 to 12 years depending on gene mutational status of immunoglobulin. While in MCL the disease shows a more clinical aggression and treatment-resistant over time, with a median survival of 3 to 7 years. Thus differentiation of these disorders has vital role prognostically and therapeutically. The conjunction of clinical features, morphology and immunological features can lead to an accurate diagnosis in the majority of the cases of B cell chronic lymphoproliferative disorders; but the diagnosis remains uncertain in a small percentage of cases. The characteristic immunophenotypic features of CLL are aberrant expression of CD5, together with CD23 expression and the negativity of CD79b and FMC7. This is in contrast to MCL, who also express CD5 and lack CD23 expression and strongly express FMC7. The most important helpful markers in their differentiation are CD23 and FMC7. MCL is CD23–ve and FMC7+ve, while CLL usually have the opposite, however aberrant phenotypes may occur as reported by previous studies… whose found that CD23 positivity in CLL ranged from 86.6 to 100% of cases while CD23 expression was found in about half of MCL cases and FMC7 positivity of 0–12% in CLL cases (10, 11) and 90–100% in MCL (10, 12) so in these cases flow cytometric discrimination of CLL from MCL can be arduous.

In this study, we scrutinized the expression of CD200 on the clonal cells of patients with B-CLL and MCL. CD200 was expressed in 94.9% CLL cases compared with 0% in MCL cases. And the results showed that there were highly significant differences between these two disorders. CD200 expression in which P was < 0.001, the results also showed that CD200 expression was negative in only two cases of B-CLL who were known to have an advanced diseases shown in table 2 according to Binet staging (stage C). CD200 positivity showed a positive predictive value of 100%, a negative predictive value of 83.33 %, a sensitivity of 94.87 %, and a specificity of 100%.

The results of this study in agree with previous studies which confirm the uniform expression CD200 on B-CLL cases and the only negative B-CLL were stage C so there may be a relation between the CD200 expression and the prognosis this need an expanded study, this agree with Alapat et al. (13) and Dahlia A. El-Sewefy et al. (14)

So the inclusion of CD200 in routine panels can be very helpful in distinguishing between these two disease, specially, in patients with inconclusive phenotypes.

Conclusion:
CD200 is highly expressed in B-CLL and it has a discriminative role in mature CD5+ve B-CLPD (B-CLL and MCL). The only CD 200 negative CLL case might related to the advanced stage of disease, so more expanded study required to correlate the CD200 expression and the prognosis of the disease.
References: -